Janux TherapeuticsJANX +2.54%47 Piotroski F-Score is 3 as of Jun. 27, 2026, which is at its 10-year median of 3.00. GuruFocus rates JANX with a GF Score™ of 47/100 and a GF Value™ of $39.28 (Possible Value Trap). The stock has 5 warning signs investors should review. Among 1,342 Biotechnology companies, Janux Therapeutics ranks better than 54.99% on this metric.
Warning Sign:
Piotroski F-Score of 3 is low, which usually implies poor business operation.
The zones of discrimination were as such:
Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3
Janux Therapeutics has an F-score of 3. It is a bad or low score, which usually implies poor business operation.
The historical rank and industry rank for Janux Therapeutics's Piotroski F-Score or its related term are showing as below:
JANX'
s Piotroski F-Score Range Over the Past 10 Years
Min: 2 Med: 3 Max: 6
Current: 3
During the past 7 years, the highest Piotroski F-Score of Janux Therapeutics was 6. The lowest was 2. And the median was 3.
The developer of the system is Joseph D. Piotroski is relatively unknown accounting professor who shuns publicity and rarely gives interviews.
He graduated from the University of Illinois with a B.S. in accounting in 1989, received an M.B.A. from Indiana University in 1994. Five years later, in 1999, after earning a Ph.D. in accounting from the University of Michigan, he became an associate professor of accounting at the University of Chicago.
He wanted to see if he can develop a system (using a simple nine-point scoring system) that can increase the returns of a strategy of investing in low price to book (referred to in the paper as high book to market) value companies.
What he found was something that exceeded his most optimistic expectations.
Buying only those companies that scored highest (8 or 9) on his nine-point scale, or F-Score as he called it, over the 20 year period from 1976 to 1996 led to an average out-performance over the market of 13.4%.
Even more impressive were the results of a strategy of investing in the highest F-Score companies (8 or 9) and shorting companies with the lowest F-Score (0 or 1).
Over the same period from 1976 to 1996 (20 years) this strategy led to an average yearly return of 23%, substantially outperforming the average S&P 500 index return of 15.83% over the same period.
Janux Therapeutics Piotroski F-Score Related Terms
Janux Therapeutics Piotroski F-Score Historical Data
* Premium members only.
The historical data trend for Janux Therapeutics's Piotroski F-Score can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
JANX vs ANNX, XNCR, SPRY: Piotroski F-Score Comparison
For the Biotechnology subindustry, Janux Therapeutics's Piotroski F-Score, along with its competitors' market caps and Piotroski F-Score data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Janux Therapeutics Piotroski F-Score vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Janux Therapeutics's Piotroski F-Score distribution charts can be found below:
* The bar in red indicates where Janux Therapeutics's Piotroski F-Score falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
*Note: If the latest quarterly/semi-annual/annual total assets data is 0, then we will use previous quarterly/semi-annual/annual data for all the items in the balance sheet.
Profitability
Question 1. Return on Assets (ROA)
Net income before extraordinary items for the year divided by Total Assets at the beginning of the year.
Score 1 if positive, 0 if negative.
Janux Therapeutics's current Net Income (TTM) was -114.48.
==> Negative ==> Score 0.
Question 2. Cash Flow Return on Assets (CFROA)
Net cash flow from operating activities (operating cash flow) divided by Total Assets at the beginning of the year.
Janux Therapeutics's return on assets of this year was -0.10894657. Janux Therapeutics's return on assets of last year was -0.11283571.
==> This year is higher. ==> Score 1.
Question 4. Quality of Earnings (Accrual)
Compare Cash flow return on assets (2) to return on assets (1)
Janux Therapeutics's gearing of this year was 0.01858769. Janux Therapeutics's gearing of last year was 0.02483581.
==> This year is lower or equal to last year. ==> Score 1.
Question 6. Change in Working Capital (Liquidity)
Compare this year's current ratio (current assets divided by current liabilities) to last year's current ratio.
Score 1 if this year's current ratio is higher, 0 if it's lower
Janux Therapeutics's current ratio of this year was 17.00838496. Janux Therapeutics's current ratio of last year was 58.46983202.
==> Last year's current ratio is higher ==> Score 0.
Question 7. Change in Shares in Issue
Compare the number of shares in issue this year, to the number in issue last year.
Score 0 if there is larger number of shares in issue this year, 1 otherwise.
Janux Therapeutics's number of shares in issue this year was 62.666. Janux Therapeutics's number of shares in issue last year was 61.792.
==> There is larger number of shares in issue this year. ==> Score 0.
Efficiency
Question 8. Change in Gross Margin
Compare this year's gross margin (Gross Profit divided by sales) to last year's.
Score 1 if this year's gross margin is higher, 0 if it's lower.
Janux Therapeutics's gross margin of this year was 1. Janux Therapeutics's gross margin of last year was 1.
==> Last year's gross margin is higher ==> Score 0.
Question 9. Change in asset turnover
Compare this year's asset turnover (total sales for the year divided by total assets at the beginning of the year) to last year's asset turnover ratio.
Score 1 if this year's asset turnover ratio is higher, 0 if it's lower
Janux Therapeutics's asset turnover of this year was 0.01306944. Janux Therapeutics's asset turnover of last year was 0.01355039.
==> Last year's asset turnover is higher ==> Score 0.
Evaluation
Piotroski F-Score
=
Que. 1
+
Que. 2
+
Que. 3
+
Que. 4
+
Que. 5
+
Que. 6
+
Que. 7
+
Que. 8
+
Que. 9
=
0
+
0
+
1
+
1
+
1
+
0
+
0
+
0
+
0
=
3
Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3
Janux Therapeutics has an F-score of 3. It is a bad or low score, which usually implies poor business operation.
Janux Therapeutics (JANX) has a Piotroski F-Score of 3 as of Jun. 27, 2026. The Piotroski F-score grades a company's business operating strength from 0-9. View historical data on Janux Therapeutics and its competitors. This is near median its historical median of 3.00. Over the past decade, Janux Therapeutics' Piotroski F-Score has ranged from 2.00 to 6.00. According to the industry distribution chart, Janux Therapeutics ranks #604 out of 1342 companies in the Biotechnology industry, placing it in the top 45%.
Is Janux Therapeutics' Piotroski F-Score too high?
Janux Therapeutics' current Piotroski F-Score of 3 is near median its 10-year median of 3.00. Over the past 10 years, this metric has ranged from a low of 2.00 to a high of 6.00. The Biotechnology industry median Piotroski F-Score is 3.00. Janux Therapeutics' value of 3 is 0% at this industry median. Based on the distribution chart, Janux Therapeutics ranks #604 out of 1342 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Janux Therapeutics has a GF Score™ of 47/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Janux Therapeutics' Piotroski F-Score compare to ANNX and XNCR?
According to the Biotechnology industry distribution chart, Janux Therapeutics ranks #604 out of 1342 companies for Piotroski F-Score. This puts Janux Therapeutics in the upper half of its industry. The industry median Piotroski F-Score is 3.00. Janux Therapeutics' value of 3 is 0% at this benchmark. Historically, Janux Therapeutics' own Piotroski F-Score has ranged from 2.00 to 6.00 over the past decade. While the company's 10-year median is 3.00 vs. the industry median of 3.00, Janux Therapeutics has consistently been at the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Piotroski F-Score for a Biotechnology company?
The median Piotroski F-Score among Biotechnology companies is 3.00, based on 1,342 companies in the industry. Companies in the top quartile (top 25%) have a Piotroski F-Score significantly above this median, while those in the bottom quartile fall well below. However, Piotroski F-Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Janux Therapeutics's current Piotroski F-Score of 3 is 0% at the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Piotroski F-Score mean?
A high Piotroski F-Score can signal that a stock is expensive relative to its fundamentals. The Piotroski F-score grades a company's business operating strength from 0-9. View historical data on Janux Therapeutics and its competitors. For the Biotechnology industry, the median Piotroski F-Score is 3.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Janux Therapeutics's current Piotroski F-Score is 3, which is near median its own 10-year median of 3.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Janux Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Janux Therapeutics (JANX) is currently considered Possible Value Trap. The stock's GF Value™ is $39.28, compared to a current price of $14.94 — trading 62% below its estimated fair value. The current Piotroski F-Score is 3, which is near median its 10-year median of 3.00 and 0% at the Biotechnology industry median of 3.00. Janux Therapeutics' overall GF Score™ is 47/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Piotroski F-Score calculated?
Piotroski F-Score is calculated from a company's financial statements. For Janux Therapeutics (JANX), the current Piotroski F-Score is 3 as of Jun. 27, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Janux Therapeutics (JANX) Overvalued in 2026?
Based on GuruFocus' analysis, Janux Therapeutics stock appears to be undervalued.
The current stock price of $14.94 is trading 62% below its estimated GF Value™ of $39.28.
GuruFocus considers Janux Therapeutics to be Possible Value Trap.
Key valuation signals for JANX:
Piotroski F-Score: 3 (near median its 10-year median of 3.00)
GF Value™: $39.28 vs. price of $14.94 (62% below fair value)
Industry Position: 0% at the Biotechnology median (#604 of 1342)
No single metric tells the full story. See the JANX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Janux Therapeutics Inc is a clinical-stage biopharmaceutical company developing tumor-activated immunotherapies for cancer. The proprietary technology of the company has enabled the development of distinct bispecific platforms: Tumor Activated T Cell Engagers (TRACTr), Tumor Activated Immunomodulators (TRACIr), and Adaptive Immune Response Modulator (ARM) platforms. The TRACTr platform produces T cell engagers (TCEs) with a tumor antigen-binding domain and a CD3 T cell binding domain, while the TRACIr platform produces bispecifics with a tumor antigen-binding domain and a costimulatory CD28 binding domain.
47GF Score
Get the complete analysis for JANX
Piotroski F-Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
JANX has been successfully added to your 
